Patients with type 2 diabetes who received sodium-glucose cotransporter-2 inhibitors had a lower risk for rheumatic disease ...

Using SGLT2 inhibitors in the first-line treatment of type 2 diabetes lowered some cardiovascular risk, a claims database study showed. The combined 12-month risk for myocardial infarction (MI), ...

Affordability of SGLT2i may contribute to the low prescription rate in CKD. Although clinical trials have demonstrated favorable cardiovascular and kidney effects from use of sodium-glucose ...

With the skyrocketing popularity of GLP-1 RAs, some lesser-known side effects, including anemia, are coming to light.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. As far as SGLT2 inhibitors for first-line therapy in ...

A GLP-1 receptor drug first designed for diabetes, Ozempic has surged in popularity as a top contender in the weight loss ...

A new study provides the first comprehensive safety profile of sodium-glucose cotransporter 2 (SGLT2) inhibitors in US patients with chronic kidney disease (CKD) and type 2 diabetes receiving routine ...

Speakers at the Institute for Value-Based Medicine event held September 18, 2025, in Nyack, New York, spoke about methods of ...

Adding sodium-glucose cotransporter 2 (SGLT2) inhibitors to standard medical therapy for heart failure with preserved ejection fraction (HFpEF) provides just low-to-intermediate economic value to the ...

Case demonstrates initiation of a sodium-glucose cotransporter-2 (SGLT2) inhibitor in a patient with type 2 diabetes and heart failure. A 56-year-old man with a history of hypertension and type 2 ...

Earlier this year, empagliflozin (Jardiance) won FDA approval for a broader indication in heart failure across the spectrum of ejection fraction. As part of our review of the year's top stories, we ...